Galimedix, Inc.

March 08, 2024
Galimedix, Inc.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

View Article
February 28, 2024
Galimedix, Inc.

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference

View Article
October 25, 2023
Galimedix, Inc.

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations (news with additional features)

View Article
NEWS